Literature DB >> 7591126

Protective efficacy of major outer membrane protein-specific immunoglobulin A (IgA) and IgG monoclonal antibodies in a murine model of Chlamydia trachomatis genital tract infection.

T W Cotter1, Q Meng, Z L Shen, Y X Zhang, H Su, H D Caldwell.   

Abstract

The protective efficacy of immunoglobulin A (IgA) and IgG monoclonal antibodies (MAbs) specific for the major outer membrane protein of Chlamydia trachomatis MoPn was evaluated in a murine genital tract infection model. MAbs were delivered into serum and vaginal secretions of naive mice by using the backpack hybridoma tumor system, and protective efficacy was assessed over the first 8 days following challenge by quantitative determination of chlamydial recovery from cervicovaginal swabs, histopathological evaluation of genital tract tissue, and immunohistochemical detection of chlamydial inclusions. IgA and IgG significantly reduced the incidence of infection following vaginal challenge with 5 50% infectious doses, but such protection was overwhelmed by 10- and 100-fold higher challenge doses. Both MAbs also consistently reduced vaginal shedding from infected animals with all three challenge doses compared with the negative control MAb, although the magnitude of this effect was marginal. Blinded pathological evaluation of genital tract tissues at 8 days postinfection showed a significant reduction in the severity of the inflammatory infiltrate in oviduct tissue of infected IgA- and IgG-treated animals. Immunohistochemical detection of chlamydial inclusions revealed a marked reduction in the chlamydial burden of the oviduct epithelium; this finding is consistent with the reduced pathological changes observed in this tissue. These studies indicate that the presence of IgA or IgG MAbs specific to major outer membrane proteins has a marginal effect in preventing chlamydial colonization and shedding from the genital tract but has a more pronounced effect on ascending chlamydial infection and accompanying upper genital tract pathology.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7591126      PMCID: PMC173675          DOI: 10.1128/iai.63.12.4704-4714.1995

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  24 in total

1.  Increased risistance of immunoglobulin A dimers to proteolytic degradation after binding of secretory component.

Authors:  E Lindh
Journal:  J Immunol       Date:  1975-01       Impact factor: 5.422

2.  Studies on the structural and conformational basis for the relative resistance of serum and secretory immunoglobulin A to proteolysis.

Authors:  B J Underdown; K J Dorrington
Journal:  J Immunol       Date:  1974-03       Impact factor: 5.422

3.  Structural differences in mouse IgA myeloma proteins of different allotypes.

Authors:  N L Warner; J J Marchalonis
Journal:  J Immunol       Date:  1972-10       Impact factor: 5.422

Review 4.  New knowledge of chlamydiae and the diseases they cause.

Authors:  J T Grayston; S Wang
Journal:  J Infect Dis       Date:  1975-07       Impact factor: 5.226

5.  Preferential transport of IgA and IgA-immune complexes to bile compared with other external secretions.

Authors:  M W Russell; T A Brown; J Mestecky
Journal:  Mol Immunol       Date:  1982-05       Impact factor: 4.407

6.  The role of immunoglobulin in the neutralization of trachoma infectivity.

Authors:  J Barenfanger; A B MacDonald
Journal:  J Immunol       Date:  1974-11       Impact factor: 5.422

7.  Humoral immunity in the resolution of genital infection in female guinea pigs infected with the agent of guinea pig inclusion conjunctivitis.

Authors:  R G Rank; H J White; A L Barron
Journal:  Infect Immun       Date:  1979-11       Impact factor: 3.441

8.  Protective efficacy of a parenterally administered MOMP-derived synthetic oligopeptide vaccine in a murine model of Chlamydia trachomatis genital tract infection: serum neutralizing IgG antibodies do not protect against chlamydial genital tract infection.

Authors:  H Su; M Parnell; H D Caldwell
Journal:  Vaccine       Date:  1995-08       Impact factor: 3.641

9.  Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis.

Authors:  H D Caldwell; J Kromhout; J Schachter
Journal:  Infect Immun       Date:  1981-03       Impact factor: 3.441

10.  Variable major proteins of Borrellia hermsii.

Authors:  A G Barbour; S L Tessier; H G Stoenner
Journal:  J Exp Med       Date:  1982-11-01       Impact factor: 14.307

View more
  88 in total

Review 1.  Immunity to murine chlamydial genital infection.

Authors:  Richard P Morrison; Harlan D Caldwell
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

2.  Protective immunity against mouse upper genital tract pathology correlates with high IFNγ but low IL-17 T cell and anti-secretion protein antibody responses induced by replicating chlamydial organisms in the airway.

Authors:  Chunxue Lu; Hao Zeng; Zhihong Li; Lei Lei; I-Tien Yeh; Yimou Wu; Guangming Zhong
Journal:  Vaccine       Date:  2011-11-10       Impact factor: 3.641

Review 3.  Mucosal immunity: overcoming the barrier for induction of proximal responses.

Authors:  Brent S McKenzie; Jamie L Brady; Andrew M Lew
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

4.  T lymphocyte immunity in host defence against Chlamydia trachomatis and its implication for vaccine development.

Authors:  X Yang; R Brunham
Journal:  Can J Infect Dis       Date:  1998-03

5.  Immunization with a combination of integral chlamydial antigens and a defined secreted protein induces robust immunity against genital chlamydial challenge.

Authors:  Weidang Li; Ashlesh K Murthy; M Neal Guentzel; James P Chambers; Thomas G Forsthuber; J Seshu; Guangming Zhong; Bernard P Arulanandam
Journal:  Infect Immun       Date:  2010-07-06       Impact factor: 3.441

6.  Intranasal vaccination with a secreted chlamydial protein enhances resolution of genital Chlamydia muridarum infection, protects against oviduct pathology, and is highly dependent upon endogenous gamma interferon production.

Authors:  Ashlesh K Murthy; James P Chambers; Patricia A Meier; Guangming Zhong; Bernard P Arulanandam
Journal:  Infect Immun       Date:  2006-11-21       Impact factor: 3.441

7.  A chlamydial type III-secreted effector protein (Tarp) is predominantly recognized by antibodies from humans infected with Chlamydia trachomatis and induces protective immunity against upper genital tract pathologies in mice.

Authors:  Jie Wang; Lili Chen; Fan Chen; Xiaoyun Zhang; Yingqian Zhang; Joel Baseman; Sondra Perdue; I-Tien Yeh; Rochelle Shain; Martin Holland; Robin Bailey; David Mabey; Ping Yu; Guangming Zhong
Journal:  Vaccine       Date:  2009-03-10       Impact factor: 3.641

8.  IL-6-mediated signaling pathways limit Chlamydia muridarum infection and exacerbate its pathogenicity in the mouse genital tract.

Authors:  Xin Sun; Qi Tian; Luying Wang; Min Xue; Guangming Zhong
Journal:  Microbes Infect       Date:  2017-08-31       Impact factor: 2.700

9.  Effects of azithromycin and rifampin on Chlamydia trachomatis infection in vitro.

Authors:  U Dreses-Werringloer; I Padubrin; H Zeidler; L Köhler
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

10.  Serovar-specific immune responses to peptides of variable regions of Chlamydia trachomatis major outer membrane protein in serovar D-infected women.

Authors:  Pragya Srivastava; Rishein Gupta; Hem Chandra Jha; Rajneesh Jha; Apurb Rashmi Bhengraj; Sudha Salhan; Aruna Mittal
Journal:  Clin Exp Med       Date:  2008-09-25       Impact factor: 3.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.